

Chromosome 21 Scan in Down Syndrome Reveals DSCAM as a Predisposing Locus in Hirschsprung Disease

Anne-Sophie Jannot^{1,2}, Anna Pelet^{1,2,9}, Alexandra Henrion-Caude^{1,2,9}, Asma Chaoui³, Marine Masse-Morel^{1,2}, Stacey Arnold⁴, Damien Sanlaville^{5,6}, Isabella Ceccherini⁷, Salud Borrego^{8,9}, Robert M. W. Hofstra¹⁰, Arnold Munnich^{1,2}, Nadège Bondurand³, Aravinda Chakravarti⁴, Françoise Clerget-Darpoux^{1,2}, Jeanne Amiel^{1,2}, Stanislas Lyonnet^{1,2*}

1 INSERM U-781, AP-HP Hôpital Necker-Enfants Malades, Paris, France, **2** Département de Génétique, Université Paris Descartes, Faculté de Médecine, Paris, France, **3** INSERM U-955, Créteil, France, **4** Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, **5** HCL, Service de génétique, Bron, France, **6** INSERM U-1028, CNRS UMR5292, Université Claude Bernard Lyon 1, Equipe TIGER, Lyon, France, **7** Laboratorio di Genetica Molecolare, Istituto Gaslini, Genova, Italy, **8** Unidad de Gestión Clínica de Genética, Reproducción y Medicina Fetal, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain, **9** CIBER de Enfermedades Raras, ISCIII, Sevilla, Spain, **10** Department of Clinical Genetics, ErasmusMC, University of Rotterdam, Rotterdam, The Netherlands

Abstract

Hirschsprung disease (HSCR) genetics is a paradigm for the study and understanding of multigenic disorders. Association between Down syndrome and HSCR suggests that genetic factors that predispose to HSCR map to chromosome 21. To identify these additional factors, we performed a dose-dependent association study on chromosome 21 in Down syndrome patients with HSCR. Assessing 10,895 SNPs in 26 Caucasian cases and their parents led to identify two associated SNPs (rs2837770 and rs8134673) at chromosome-wide level. Those SNPs, which were located in intron 3 of the *DSCAM* gene within a 19 kb-linkage disequilibrium block region were in complete association and are consistent with *DSCAM* expression during enteric nervous system development. We replicated the association of HSCR with this region in an independent sample of 220 non-syndromic HSCR Caucasian patients and their parents. At last, we provide the functional rationale for the involvement of *DSCAM* by network analysis and assessment of SOX10 regulation. Our results reveal the involvement of *DSCAM* as a HSCR susceptibility locus, both in Down syndrome and HSCR isolated cases. This study further ascertains the chromosome-scan dose-dependent methodology used herein as a mean to map the genetic bases of other sub-phenotypes both in Down syndrome and other aneuploidies.

Citation: Jannot A-S, Pelet A, Henrion-Caude A, Chaoui A, Masse-Morel M, et al. (2013) Chromosome 21 Scan in Down Syndrome Reveals DSCAM as a Predisposing Locus in Hirschsprung Disease. PLoS ONE 8(5): e62519. doi:10.1371/journal.pone.0062519

Editor: Sudha Chaturvedi, Wadsworth Center, United States of America

Received: October 22, 2012; **Accepted:** March 20, 2013; **Published:** May 6, 2013

Copyright: © 2013 Jannot et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by the French National Research Agency (ANR, grants MRARE-HirGenet to SL, EvoDevoMut Grant, and ERare-HSCR Consortium to SL, IC, and SB), the Fondation pour la Recherche Médicale (FRM) to SL and JA; Fondation Jérôme Lejeune; the USA National Institutes of Health (R37 HD28088 to A.C.); the Italian Telethon (GGP04257 to IC); Fondo de Investigación Sanitaria. Instituto de Salud Carlos III (PI10/01290) and Consejería de Innovación, Ciencia y Empresa de la Junta de Andalucía (CTS-2590) to S.B.; the NWO (901-04-225) Bernouille Foundation and Ubbo Emmius Foundation to R.M.W.H. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: stanislas.lyonnet@inserm.fr

These authors contributed equally to this work.

Introduction

Hirschsprung disease (HSCR, aganglionic megacolon) is the most frequent genetic cause of congenital intestinal obstruction. The *RET* gene, which maps on chromosome 10 (10q11.2) and encodes a tyrosine kinase receptor, is implicated in the vast majority of HSCR cases, both isolated and syndromic cases [1]. Patients harbor either mutations in the coding sequence [2,3] or a non-coding polymorphism (rs2435357) in an enhancer element located in intron 1 leading to a decreased *RET* allele expression, which defines a hypomorphic allele [4].

Genetic factor(s) on chromosome 21 are suspected to increase HSCR susceptibility. First, Down syndrome (DS) is the most frequent (i.e. >90%) chromosomal anomaly in HSCR and occurs in 2–10% of cases [2]. Down syndrome patients with HSCR (HSCR-DS) have no *RET* mutation in the coding sequence but a

significantly increased frequency and over-transmission of a hypomorphic T allele in *RET* at rs2435357 SNP [1,5,6]. Two approaches have been used to identify genetic factors on chromosome 21 in these patients. The first one was to determine the shorter region of overlap (SRO) between segmental trisomy 21 and HSCR. This led to identify a region spanning 33.5–46.25 Mb on chromosome 21 [7]. The second approach consisted to analyze gene expression studies in the enteric nervous system of HSCR mouse models. This led to identify 9 genes mapping to the syntenic mouse DS critical region [8]. However, the involvement of these genes in HSCR was not confirmed in 62 patients with DS and HSCR [5]. Hitherto, no gene on chromosome 21 was demonstrated to increase their susceptibility to HSCR.

Here, we performed a chromosome scan to test for association with chromosome 21 on a series of Caucasian patients with DS and HSCR and their parents. A genome-wide scan on a cohort of




Figure 1. Chromosome-21-wide p-values for the HSCR-DS sample.

doi:10.1371/journal.pone.0062519.g001

isolated Caucasian HSCR cases and their parents was used for validation.

Patients and Methods

Patients

The chromosome-wide association sample, referred to as the HSCR-DS sample, consisted in 26 triads collected through the International Hirschsprung Disease Consortium in which the proband had both HSCR and Down syndrome. Among them, 12 were recruited in France, 8 in the USA, 4 in Spain, one in The Netherlands and one in Italy.

The validation sample consisted of DNA from 220 Caucasian cases with isolated HSCR and their parents, referred to as the isolated-HSCR sample, also collected through the International Hirschsprung Disease Consortium.

Genotyping

An Affymetrix GeneChip Human Mapping 6.0 run in McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, was available for the chromosome-wide association study.

Genotyping was performed using R 2.15.2 software by taking the following steps: (i) intensity extraction (3 intensities per SNP allele using packages `pd.genomewide.6` and `oligoClasses` [9,10]), (ii) normalization (i.e. ratio of the mean intensity obtained for one of the SNP allele divided by the sum of all 6 intensities obtained for the SNP), and (iii) genotype calling. Genotype calling was performed using the K-means method for independent individuals (`kmeans` function). As this method does not use information on pedigree, the genotypes that are not possible under Mendelian law are also called. Therefore, we used an adaptation from the K-means method that incorporates the pedigree information by updating all members of a family together [11]. To do so, we applied the R code for the family-based genotype calling methods (`SNPCaller`, function `mkmeans.tri`) to our dataset. While either methods, whether K-means or its adaptation to family-based design, showed good performance in simulated datasets, the performance was better for the K-means method adapted to

family-based design [11]. But, in order to apply the K-means method adapted for family-based design, we first called genotypes by the K-means method for independent individuals to infer the non-disjoining parent (NDJP) and the correctly disjoining parent (CDJP) as described below. Calling was performed by clustering all SNPs of a given trio rather than clustering for each SNP, because the number of observations for each SNP was too low to cluster (e.g. in trisomic children, there were only 26 observations to infer 4 clusters). When calling genotypes using the K-means method for independent individuals, we inferred the NDJP and the CDJP using the following properties:

- consider a SNP with allele A and B and (G1,G2,G3) a trio genotype with G1, G2 and G3 being respectively the father, mother and trisomic child genotype.
- if the father is the non-disjoining parent, then the following trio genotypes are not possible under Mendelian law: F1 = (AA,A-B,ABB) and F2 = (BB,AB,AAB)
- if the mother is the non-disjoining parent, then the following trio genotypes are not possible under Mendelian law: M1 = (AB,AA,ABB) and M2 = (AB,BB,AAB)
- when genotypes are called with the K-means method for independent individuals, the configurations that are not possible under Mendelian law are not discarded. But these configurations should rarely be called. For instance, M1 and M2 configurations should rarely be called if the mother is the non-disjoining parent.
- as a consequence the NDJP should be the mother if the number of M1 and M2 trios among trios with heterozygotes mother is significantly greater than the number of F1 and F2 trios among trios with heterozygotes father; the NDJP should be the father if it is significantly lower.

Once the non-disjoining parent was defined, we called genotypes using the adaptation of the K-means method to family-based data. We discarded SNPs with more than 25% of discrepancies between the calls given by the two methods in children. We also checked for Hardy-Weinberg equilibrium in parents and discarded those SNPs with a p-value below 10^{-4} .

For the isolated-HSCR sample, genotypes were extracted from the Affymetrix 500 K Array Set (250 K *NspI* and *SlyI* array). 125 triads were run on the *NspI* array, 128 on the *SlyI* array (33 on both arrays). Genotypes were called by the stand-alone command-line BRLMM (Bayesian Robust Linear Model with Mahalanobis distance) program [12]. SNPs with a MAF < 5%, departing from HWE ($p < 0.05$) or with a call rate below 80% were removed.

Statistical Analysis

All analyses were performed using R 2.15.2 software. Due to the size-constraint of our trisomic sample, we chose an extension of the case/pseudo-control test to test the association between each SNP and HSCR. In contrast to a method based on numerical optimisation of maximum likelihood, the issue of parameter estimation does not appear with small sample size contrarily to the trisomic transmission disequilibrium test proposed as stated by Xu et al [13]. The extension of the case/pseudo-control test to trisomic sample is based on the following method.

Let assume a SNP with alleles A and a:

- X the number of A alleles in the mother genotype (X = 0, 1 or 2)
- Y the number of A alleles in the father genotype (Y = 0, 1 or 2)




Figure 2. HapMap release 27 phase II+III, Feb09, on NCBI B36 assembly, linkage disequilibrium plot for CEU sample for the region spanning 40,950 kb to 40,980 kb on human chromosome 21.
doi:10.1371/journal.pone.0062519.g002

- Z1 the number of A alleles in the child genotype ($X = 0, 1, 2$ or 3)
- Z2 the number of A alleles in the pseudo-control genotype ($X = 0, 1, 2$ or 3) determined by the following equations:
 - $Z2 = 2X + Y - Z1$ in the case of maternal non-disjunction
 - $Z2 = X + 2Y - Z1$ in the case of paternal non-disjunction

In the case of no association, then we have $Z1 - Z2 = 0$.

We therefore tested the hypothesis of no association for each SNP using a Wilcoxon paired test.

To illustrate the construction of pseudo-controls, suppose the mating type is $AA \times Aa$ where the Aa parent is the non-disjoining parent. Then the correctly disjoining parent must contribute to an A allele for both the case and the pseudo-control. The non-disjoining parent contributes Aa if the two chromosomes are not reduced to homozygosity. Therefore four gametes result from the meiosis: two diploid gametes Aa and two gametes with no chromosome. Two trisomic children could result from this couple, both with AAa genotypes, therefore both the transmitted and the untransmitted alleles are Aa and the case and the pseudo-control will have the same AAa genotype. If the two chromosomes of the non-disjoining parent are reduced to homozygosity, two diploid gametes could be formed by the non-disjoining parent: AA and aa . In this case, the case and pseudo-control genotypes would be AAA and Aaa respectively or the reverse.

For the isolated HSCR sample, we tested association using a Wilcoxon paired test comparing cases and their pseudo-controls.

Odds-ratios and corresponding 95% confidence interval were estimated using formulas proposed by Kazeem and Farrall [14].

To correct for multiple testing, we permuted cases and pseudo-controls status while keeping genotypes the same.

Network Analysis

To analyze the biological involvement of the results, we also used an interactive and manually annotated database, which is derived from literature publications on proteins from the GWAS (MetaCore™, GeneGo, St Joseph, MI, USA). The GeneGo platform comprises signaling and metabolic pathways, which are manually curated. The database comprises approximately 700 representations of human and rodent signaling and metabolic pathways. The enrichment calculation uses the Fisher exact test or hypergeometric distribution to calculate the probability that the degree of overlap between the list of possible protein targets generated from the query compounded analysis and the protein represented in the functional ontology category can happen by chance, given an identical number of proteins selected at random from the protein universe annotated within the ontology.

Analysis of SOX10 Binding Sites

Search for SOX10-binding sites was performed in silico using <http://rvista.dcode.org/>. Gel shift experiments were performed using truncated SOX10 versions (amino acids 1–188, 5 μg /reaction) and 0.5 ng of ^{33}P -labeled probe A: 5'-GATCAATGCAGTGAAGTCAGTGATAAGT-3' and probe B: 5'-GATCAATGCAGTGAAGTCAGTGGTAAGT-3' as previously described [15]. Probes containing one or two SOX10-binding sites from the *MITF* or *Cx32* promoter regions were used as controls (for sequences see [16,17]). The two putative SOX10 binding sites identified are underlined in probe A.

Table 1. Genotype at rs2837770 for the 26 triads.

Triad number	CDJP	NDJP	Case
1	AG	AG	AAG
2	AG	GG	AGG
3	GG	AA	AAG
4	AA	GG	AGG
5	AG	AG	AAG
6	AG	AG	AAA
7	AG	GG	AGG
8	AG	AG	AAG
9	AA	GG	AGG
10	GG	GG	GGG
11	GG	AG	AGG
12	GG	GG	GGG
13	AA	AG	AAG
14	AA	AA	AAA
15	AG	AG	AAG
16	AG	AA	AAA
17	GG	GG	GGG
18	AG	AA	AAA
19	AG	AA	AAA
20	AG	AA	AAA
21	AG	GG	AGG
22	AG	GG	AGG
23	AG	AG	AAG
24	GG	GG	GGG
25	AA	AG	AAA
26	AG	GG	AGG

CDJP: Correctly disjoining parent.

NDJP: Non-disjoining parent.

doi:10.1371/journal.pone.0062519.t001

Ethics Statement

Ethical committee “Ile de France II” (Project AOM95224, P959892) approved the study protocol. Written informed consent was obtained from all study participants and/or their legal guardians.

Results

Association Analysis in the HSCR-DS Sample

SNP-genotyping on chromosome 21 was carried out in 26 Caucasian patients with DS and HSCR and their parents for 12,579 SNPs in chromosome 21. When calling genotypes with the K-means method for independent individuals, the number of M1 and M2 trios among trios with heterozygotes mother was significantly greater than the number of F1 and F2 trios among trios with heterozygotes father for all trios but one for which it was significantly lower (see Table S1). Therefore, we were able to infer a maternal non-disjunction for all trios but one displaying paternal non-disjunction.

1,065 SNPs (8.5%) were discarded because of Hardy Weinberg disequilibrium in parents. Additional 181 SNPs (1.5%) were discarded because children genotype calls performed using K-means for independent individuals and for trios data differed in

more than 6 SNPs (25% of the SNPs). Therefore, 11,333 SNPs (90%) were tested for association with HSCR.

As shown in Figure 1, top p-value signals were achieved by 2 SNPs in complete association except in one parent: rs2837770 and rs8134673, both located in intron 3 of *DSCAM*. Detailed genotypes are indicated in Table 1. Of note, 24 parents out of 52 were heterozygous for rs2837770 and 23 parents for rs8134673. Nominal p-value for rs2837770 and rs8134673 were respectively $p = 1.5 \times 10^{-4}$ and $p = 2.4 \times 10^{-4}$ and after correction for multiple testing $p = 0.02$ and 0.04 . Both SNPs co-localized to the same linkage disequilibrium block, spanning from 40,954 kb to 40,973 kb (hg18), and encompassing an exon-free region (Figure 2). Of note, we applied the trisomic transmission disequilibrium test to rs2837770 that we implemented using the function `optim` (method “L-BFGS-B”) in R 2.15.2 software and found very similar p-value ($p = 0.00026$). Within this region, 18 SNPs were successfully genotyped, and 7 of them were associated with nominal $p < 0.05$ (Table 2). We thus focused on this region for the validation step.

Validation of the Association in the HSCR Non-syndromic Sample

We further tested the association between HSCR and all SNPs of the 19 kb-long region spanning from 40,954 kb to 40,973 kb using the isolated-HSCR sample, typed on either the *NspI* array ($n = 125$) and/or the *SpyI* array ($n = 128$). For this sample, 5 SNPs were successfully genotyped, among which rs2837770 was the only one in common to our previous analysis (Table 3). We found that rs2837780 was strongly associated to HSCR in this validation sample (nominal $p = 0.00065$, $p = 0.0032$ after a Bonferroni correction for 5 SNPs). Of note, rs2837780 was not associated to HSCR in the HSCR-DS sample, but showed departure from Hardy-Weinberg disequilibrium ($p = 0.03$). This could be an indirect argument in favour of association with HSCR [18].

Characterization of *DSCAM* Involvement

We then questioned systems biology protein networks on *DSCAM* gene. To this end, we allowed the platform to build network for nervous system development. As shown in Figure 3, we focused on *DSCAM* as a prioritized network object, using filters on brain, fetal brain and colon as tissue of expression (Figure 3). Careful analysis of the network unravelled the involvement of *neuregulin-1* (*NRG-1*), an HSCR gene [19], in the same pathway.

To gain further insights into the functionality of the association results, we studied the 19 kb-long region spanning 40,954 kb to 40,973 kb in terms of conserved composite motif discovery for SOX10-binding sites. Indeed, SOX10 is a key transcriptional regulator of neural crest development, which also regulates *RET* gene. We found that the A allele of rs2837778 was part of a SOX10-binding site, unlike the G allele. Interestingly, we observed that the A allele at rs2837778 was in complete association with the T allele of rs2837780 in HapMap CEU population (1000genomes CEU low coverage). Other putative SOX10-binding sites were identified close by, one of them corresponding to a conserved binding site (both binding sites are underlined in the probe sequence provided in materials and methods). Interestingly both sites are pointing towards each other and separated by 9 pb, a configuration previously described as optimal for dimeric SOX10 binding [20]. Thus, we further challenged the possibility of SOX10 to effectively bind this sequence. By electrophoretic mobility shift assay, we detected a significant dimeric binding of SOX10 to a *DSCAM* fragment carrying the A allele whereas reduced binding was observed with the G allele (Figure 4).

Table 2. Association results for the SNPs in the region spanning 40954 kb to 40973 kb on chromosome 21 for the sample with DS and HSCR.

Variant	Position	Minor allele	Major allele	MAF in HapMap CEU sample	MAF in pseudos	MAF in cases	HWE	Case-pseudos test p-value	T	U	OR	CI 95%
rs8133190	40954866	C	T	0.12	0.15	0.08	0.65	0.10	11	5	2.20	0.76 6.33
rs2837770	40956222	A	G	0.41	0.31	0.55	0.57	0.00015	7	26	0.27	0.12 0.62
rs7279710	40957328	T	C	0.12	0.14	0.09	0.65	0.20	6	10	0.60	0.22 1.65
rs6517605	40957682	C	T	0.57	0.47	0.63	0.86	0.04	11	23	0.48	0.23 0.98
rs4818152	40958090	T	C	0.13	0.22	0.13	0.66	0.16	9	16	0.56	0.25 1.27
rs2837772	40960044	T	C	0.31	0.31	0.24	0.85	0.48	17	12	1.42	0.68 2.97
rs8127441	40960563	G	A	0.39	0.31	0.58	0.34	0.0004	6	27	0.22	0.09 0.54
rs9984320	40960601	T	C	NA	0.47	0.64	0.86	0.01	14	27	0.52	0.27 0.99
rs2142126	40961286	G	C	0	0.03	0.01	0.89	1.00	1	2	0.50	0.05 5.51
rs2837773	40961880	C	A	0.42	0.46	0.35	0.52	0.19	20	11	1.82	0.87 3.79
rs9977945	40962128	T	C	0.12	0.15	0.08	0.65	0.10	11	5	2.20	0.76 6.33
rs9977484	40962357	G	C	NA	0.17	0.05	0.30	0.02	13	4	3.25	1.06 9.97
rs8130310	40962412	C	G	NA	0.1	0.13	0.65	0.64	9	7	1.29	0.48 3.45
rs2837774	40962525	C	T	NA	0.46	0.36	0.01	0.30	18	10	1.80	0.83 3.90
rs8134673	40970181	A	G	0.39	0.27	0.55	0.63	0.00024	6	28	0.21	0.09 0.52
rs2178848	40970468	A	G	0.5	0.47	0.33	0.08	0.03	21	10	2.10	0.99 4.46
rs4818160	40972146	T	C	0.5	0.47	0.56	0.99	0.29	24	17	1.41	0.76 2.63
rs2837780	40972828	C	T	0.3	0.28	0.31	0.03	0.65	10	12	0.83	0.36 1.93

MAF: minor allele frequency, HWE: Hardy Weinberg Equilibrium test p-value, T: number of minor alleles transmitted to the affected case from heterozygotes parents, U: number of minor alleles untransmitted to the affected case from heterozygotes parents, CI 95%: 95% confidence intervals for odds-ratio, OR: odds-ratio.
doi:10.1371/journal.pone.0062519.t002

Discussion

For long, *DSCAM* has been regarded as an appealing candidate gene accounting for the increased prevalence of HSCR in patients with DS. *DSCAM* was shown to map to HSCR critical region [7] in patients with DS as well as to the genomic region associated with HSCR in a large Mennonite kindred [21]. However, its involvement in HSCR epidemiology had never been provided since then, as recently underlined by different studies, which aimed at discovering the genes involved in HSCR on chromosome 21 [5,22]. Our results point to *DSCAM* as a predisposing locus to HSCR in patients with DS. We first identified two SNPs, rs2837770 and rs8134673 that co-localize to the same linkage disequilibrium block encompassing an exon-free region of 19 kb in length of the *DSCAM* gene, in association with HSCR in our HSCR-DS sample. This association was then replicated using an

independent sample of isolated HSCR cases (without DS). Consistently, rs2837770 was recently shown to be associated to HSCR in a Chinese population [23]. We thus propose that the involvement of *DSCAM* in HSCR susceptibility will be encountered in most ethnical backgrounds.

Remarkably, a great variety of arguments from the literature converge to emphasize the relevance of *DSCAM* to HSCR. Beyond genetic analyses, the expression and the function of *DSCAM* are both relevant to HSCR. *In situ* hybridization analyses of the mouse *Dscam* gene revealed a broad expression pattern within the nervous system at the time of neuronal differentiation namely in the neural tube, cortex, hippocampus, medulla, spinal cord and most neural crest-derived tissues [24]. Furthermore, mice deficient for *Dscam* display a significant loss of pre-inspiratory neuron synchronicity and perinatal death, similar to congenital central hypoventilation

Table 3. Association results for the SNPs in the region spanning 40954 kb to 40973 kb for the isolated HSCR sample.

Variant	Position	Number of cases-pseudos pairs	Minor allele	Major allele	MAF in cases	MAF in pseudo-controls	p-value	T	U	OR	CI for OR
rs2837770	40956222	120	A	G	0.44	0.36	0.09	67	49	1.37	[0.95; 1.97]
rs7279710	40957328	124	T	C	0.12	0.14	0.48	26	32	0.81	[0.48; 1.37]
rs9977945	40962128	111	T	C	0.12	0.14	0.46	23	29	0.79	[0.45; 1.37]
rs2837774	40962525	122	C	T	0.42	0.48	0.17	52	67	0.78	[0.55; 1.11]
rs2837780	40972828	112	C	T	0.2	0.34	0.00065	28	58	0.49	[0.31; 0.76]

doi:10.1371/journal.pone.0062519.t003




Figure 3. Network involving *DSCAM* in autonomous nervous system development. Using the MetaCore platform, this biological network was established after filtering *DSCAM* as network objects. *DSCAM*, the only protein subjected to the filters of expression, is encircled. doi:10.1371/journal.pone.0062519.g003




Figure 4. Electrophoretic mobility shift assays using the dimeric binding site from the *Cx32* (line 1 and 2), the monomeric binding site from the *MITF* (line 3 and 4) promoter regions, *DSCAM* probes containing the A allele from rs2037778 (probe A; line 6, 7 and 11) or the G allele (probe B; lines 8, 9 and 12), and empty pECE vector (-), or SOX10. The last two wells correspond to probes A and B alone. doi:10.1371/journal.pone.0062519.g004

syndrome (Ondine’s curse), in which patients are predisposed to HSCR [25]. Moreover, *DSCAM* is a receptor for netrin-1 [26,27]. Netrin-mediated guidance is essential for the development of submucosal ganglia [28]. Mice mutant for deleted-in-colorectal-carcinoma (DCC), which is a netrin-1 dependence receptor, lack submucosal gut ganglia [29]. Vagal neural crest-derived precursors of the enteric nervous system colonize the bowel rostro-caudally within the enteric mesenchyme. Orthogonal secondary migrations, towards the mucosa, result in the formation of submucosal ganglia. This perpendicular migration is in part mediated by netrins that are known to be expressed in the mucosa of the fetal intestine [30]. Thus, a role of *DSCAM* in the secondary migration of neurons in the gut, being a RET-independent pathway, could explain why the *DSCAM* gene was not differentially expressed in the enteric nervous system of *Ret* mutant mice compared to controls [22]. Interestingly, the pathway analysis conducted herein reveals further links between *DSCAM* and HSCR. In particular, *NRG-1*, a gene in the network was shown to be associated to HSCR in a genome-wide analysis of a Chinese cohort [19,31], and also in a Spanish cohort [32]. In fact, *NRG-1* is a ligand of *ErbB2* and *ErbB3*, which are essential for development of the sympathetic nervous system [33]. Both receptors have been localized in enteric neurons [34] and are known to activate estrogens receptors [35]. Of note, *DSCAM* expression is sensitive to estrogens via a clustering of 10 estrogens receptor binding sites in the same intron downstream the linkage disequilibrium where the SNPs associated to HSCR lie [36]. Estrogens have also been shown to regulate the major HSCR gene, *RET* [37].

DSCAM is also known as a member of the large family of cell-adhesion molecules. Interestingly, *LICAM*, which is another gene from this family, predisposes to HSCR. Indeed, *LICAM* mutations have been ascribed to a X-linked hydrocephaly syndrome (MIM) with predisposition to HSCR [38,39,40]. *LICAM* is expressed in

the enteric nervous system [22] and is required for chain migration of neural crest cells in the developing mouse gut [41]. An interaction between *LICAM* and *SOX10*, a HSCR gene [42], was shown to significantly impair neural crest migration towards the developing gut [43]. Because *SOX10*, which is known as a key transcriptional regulator of neural crest development [42,44] regulates *RET*, the major HSCR locus, via binding to very similar consensus sequences within *RET* intron 1, we examined the exon-free region of 19 kb for *SOX10* regulation. Both *in silico* and *in vitro* analysis showed that allele A at rs2837778, a SNP in complete association to the most associated SNP in the isolated-HSCR sample, unravels a *SOX10*-binding site. Such regulatory mechanism would explain why both abnormal dosage and allelic differences could modify susceptibility to HSCR.

Association studies dealing with trisomic patients performed thus far not only never focused on HSCR but also never implied any chromosome 21-wide association study. Most studies involving patients with DS dealt with congenital heart defects, which is a frequent DS-associated phenotype and tested for association with specific genes, loci or gene pathways on chromosome 21. Locke et al [45] focused on genes involved in the folate metabolism using a large sample of trios for DS cases with congenital heart diseases and a control sample of trios for DS cases without congenital heart defect and their parents. Xu et al [13] proposed a trisomic transmission disequilibrium test and applied their method to a SNP located in *SH3BGR*, a gene expressed in fetal heart tissue and located in the DS critical region for congenital heart defect. Kerstann et al [46] performed an association study (case-control and a transmission disequilibrium test) to the region shown to be the minimal critical region for congenital heart defect on chromosome 21. None of these studies were conclusive. Therefore,

our chromosome 21-scan study provides a new methodology to unravel the genetic determinism of other sub-phenotypes in DS patients. As a future step, it will be of interest to assess whether the most associated SNPs in *DSCAM* exhibit SNP frequencies in patients with DS but not with HSCR that are similar to the ones in the general population.

Supporting Information

Table S1 Number of F1 and F2 configurations (F1+F2) and M1 and M2 configurations (M1+M2) when calling genotypes with the K-means method for independent individuals.

(DOC)

Acknowledgments

This study is a contribution from The International Hirschsprung Disease Consortium. We wish to thank the numerous patients, families and referring physicians across the world that have participated in studies of Hirschsprung disease in our laboratories, in particular Marie-Christine de Blois, Brigitte Gilbert-Dussardier, Alice Goldenberg, Muriel Holder, Hubert Journel, Hubert Lardy, Marie-Odile Rethoré, Yann Revillon and Annick Toutain.

Author Contributions

Read and commented on the earlier drafts of this manuscript: AP FCD IC SL A.Chakravarti. Conceived and designed the experiments: ASJ AP AHC DS IC SB RMWH AM NB JA SL A. Chakravarti. Performed the experiments: AC SA AP AHC NB A.Chaoui A. Chakravarti. Analyzed the data: ASJ AHC JA. Contributed reagents/materials/analysis tools: ASJ MMM. Wrote the paper: ASJ AHC JA NB FCD.

References

- de Pontual L, Pelet A, Clement-Ziza M, Trochet D, Antonarakis SE, et al. (2007) Epistatic interactions with a common hypomorphic *RET* allele in syndromic Hirschsprung disease. *Hum Mutat* 28: 790–796.
- Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, et al. (2008) Hirschsprung disease, associated syndromes and genetics: a review. *J Med Genet* 45: 1–14.
- Gabriel SB, Salomon R, Pelet A, Angrist M, Amiel J, et al. (2002) Segregation at three loci explains familial and population risk in Hirschsprung disease. *Nat Genet* 31: 89–93.
- Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, et al. (2005) A common sex-dependent mutation in a *RET* enhancer underlies Hirschsprung disease risk. *Nature* 434: 857–863.
- Arnold S, Pelet A, Amiel J, Borrego S, Hofstra R, et al. (2009) Interaction between a chromosome 10 *RET* enhancer and chromosome 21 in the Down syndrome-Hirschsprung disease association. *Hum Mutat* 30: 771–775.
- Moore SW, Zaahl MG Intronic *RET* gene variants in Down syndrome-associated Hirschsprung disease in an African population. *Journal of Pediatric Surgery* 47: 299–302.
- Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, et al. (2009) The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. *Proc Natl Acad Sci U S A* 106: 12031–12036.
- McCallion AS, Emison ES, Kashuk CS, Bush RT, Kenton M, et al. (2003) Genomic variation in multigenic traits: Hirschsprung disease. *Cold Spring Harb Symp Quant Biol* 68: 373–381.
- Carvalho B pd.genomewidensnp.6: Platform Design Info for Affymetrix GenomeWideSNP_6. R package version 0.4.2 ed.
- Carvalho B, Scharpf R oligoClasses: Classes for high-throughput SNP arrays. R package version 1.4.0 ed.
- Lin Y, Tseng GC, Cheong SY, Bean LJH, Sherman SL, et al. (2008) Smarter clustering methods for SNP genotype calling. *Bioinformatics* 24: 2665–2671.
- Affymetrix (2006) BRLMM: an Improved Genotype Calling Method for the GeneChip® Human Mapping 500 K Array Set.
- Xu Z, Kerstann KF, Sherman SL, Chakravarti A, Feingold E (2004) A trisomic transmission disequilibrium test. *Genet Epidemiol* 26: 125–131.
- Kazem GR, Farrall M (2005) Integrating Case-control and TDT Studies. *Annals of human genetics* 69: 329–335.
- Peirano RI, Goerich DE, Riethmacher D, Wegner M (2000) Protein zero gene expression is regulated by the glial transcription factor Sox10. *Mol Cell Biol* 20: 3198–3209.
- Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, et al. (2001) Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor *SOX10*. *Human molecular genetics* 10: 2783–2795.
- Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, et al. (2000) Interaction among *SOX10*, *PAX3* and *MITEF*, three genes altered in Waardenburg syndrome. *Human molecular genetics* 9: 1907–1917.
- Nielsen DM, Ehm MG, Weir BS (1998) Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. *American journal of human genetics* 63: 1531–1540.
- Garcia-Barcelo MM, Tang CS, Ngan ES, Lui VC, Chen Y, et al. (2009) Genome-wide association study identifies *NRG1* as a susceptibility locus for Hirschsprung's disease. *Proceedings of the National Academy of Sciences* 106: 2694.
- Peirano RI, Wegner M (2000) The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. *Nucleic Acids Research* 28: 3047–3055.
- Puffenberger EG, Kauffman ER, Bolk S, Matisse TC, Washington SS, et al. (1994) Identity-by-descent and association mapping of a recessive gene for Hirschsprung disease on human chromosome 13q22. *Hum Mol Genet* 3: 1217–1225.
- Heaneu TA, Pachnis V (2006) Expression profiling the developing mammalian enteric nervous system identifies marker and candidate Hirschsprung disease genes. *Proc Natl Acad Sci U S A* 103: 6919–6924.
- Liu Y, Lee Y, Ng M (2011) SNP and gene networks construction and analysis from classification of copy number variations data. *BMC Bioinformatics* 12: S4.
- Yamakawa K, Huot YK, Haendelt MA, Hubert R, Chen XN, et al. (1998) *DSCAM*: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. *Hum Mol Genet* 7: 227–237.
- Amano K, Fujii M, Arata S, Tojima T, Ogawa M, et al. (2009) *DSCAM* deficiency causes loss of pre-inspiratory neuron synchronicity and perinatal death. *J Neurosci* 29: 2984–2996.
- Liu G, Li W, Wang L, Kar A, Guan KL, et al. (2009) *DSCAM* functions as a netrin receptor in commissural axon pathfinding. *Proc Natl Acad Sci U S A* 106: 2951–2956.
- Ly A, Nikolaev A, Suresh G, Zheng Y, Tessier-Lavigne M, et al. (2008) *DSCAM* is a netrin receptor that collaborates with *DCC* in mediating turning responses to netrin-1. *Cell* 133: 1241–1254.

28. Gershon MD (2010) Developmental determinants of the independence and complexity of the enteric nervous system. *Trends Neurosci* 33: 446–456.
29. Jiang Y, Liu MT, Gershon MD (2003) Netrins and DCC in the guidance of migrating neural crest-derived cells in the developing bowel and pancreas. *Dev Biol* 258: 364–384.
30. Gershon MD, Ratchiff EM (2004) Developmental biology of the enteric nervous system: pathogenesis of Hirschsprung's disease and other congenital dysmotilities. *Semin Pediatr Surg* 13: 224–235.
31. Tang CSM, Ngan ESW, Tang WK, So MT, Cheng G, et al. (2012) Mutations in the *NRG1* gene are associated with Hirschsprung disease. *Human genetics* 131: 67–76.
32. Luzon-Toro B, Torroglosa A, Nunez-Torres R, Enguix-Riego MV, Fernandez RM, et al. (2012) Comprehensive Analysis of *NRG1* Common and Rare Variants in Hirschsprung Patients. *PLoS one* 7: e36524.
33. Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, et al. (1998) The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. *Genes & development* 12: 1825.
34. Campbell-Thompson M, Reyher KK, Wilkinson LB (2001) Immunolocalization of estrogen receptor alpha and beta in gastric epithelium and enteric neurons. *Journal of endocrinology* 171: 65.
35. St-Laurent V, Sanchez M, Charbonneau C, Tremblay A (2005) Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. *The Journal of Steroid Biochemistry and Molecular Biology* 94: 23–37.
36. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. *Cell* 122: 33–43.
37. Stine ZE, McGaughey DM, Bessling SL, Li S, McCallion AS Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer. *Human molecular genetics* 20: 3746–3756.
38. Okamoto N, Del Maestro R, Valero R, Monros E, Poo P, et al. (2004) Hydrocephalus and Hirschsprung's disease with a mutation of *L1CAM*. *J Hum Genet* 49: 334–337.
39. Okamoto N, Wada Y, Goto M (1997) Hydrocephalus and Hirschsprung's disease in a patient with a mutation of *L1CAM*. *J Med Genet* 34: 670–671.
40. Parisi MA, Kapur RP, Neilson I, Hofstra RM, Holloway LW, et al. (2002) Hydrocephalus and intestinal aganglionosis: is *L1CAM* a modifier gene in Hirschsprung disease? *Am J Med Genet* 108: 51–56.
41. Anderson RB, Turner KN, Nikonenko AG, Hemperly J, Schachner M, et al. (2006) The cell adhesion molecule 11 is required for chain migration of neural crest cells in the developing mouse gut. *Gastroenterology* 130: 1221–1232.
42. Southard-Smith EM, Kos L, Pavan WJ (1998) Sox10 mutation disrupts neural crest development in Dom Hirschsprung mouse model. *Nat Genet* 18: 60–64.
43. Wallace AS, Schmidt C, Schachner M, Wegner M, Anderson RB (2010) *L1cam* acts as a modifier gene during enteric nervous system development. *Neurobiol Dis* 40: 622–633.
44. Herbarth B, Pingault V, Bondurand N, Kuhlbrodt K, Hermans-Borgmeyer I, et al. (1998) Mutation of the Sry-related Sox10 gene in Dominant megacolon, a mouse model for human Hirschsprung disease. *Proceedings of the National Academy of Sciences* 95: 5161.
45. Locke AE, Dooley KJ, Tinker SW, Cheong SY, Feingold E, et al. (2010) Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down syndrome. *Genet Epidemiol* 34: 613–623.
46. Kerstann KF, Feingold E, Freeman SB, Bean LJ, Pyatt R, et al. (2004) Linkage disequilibrium mapping in trisomic populations: analytical approaches and an application to congenital heart defects in Down syndrome. *Genet Epidemiol* 27: 240–251.